罗氏万赛维的图片及介绍

(Valganciclovir Hydrochloride Tablets) is a prodrug of the antiviral drug ganciclovir developed by the Swiss company Roche. In March 2001, the drug was approved by the U.S. FDA. It was first launched in the United States in May 2001. It was the first oral drug to treat cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Its indications were expanded in May 2003. For the prevention and treatment of secondary CMV infection in organ transplant recipients.

The results of a 12-month phase III clinical trial of Roche's Valcyte (i.e. Valcyte) showed that it was comparable to the standard treatment Cytovene (ganciclovir, ganciclovir) in reducing the incidence of cytomegalovirus infection in solid organ transplant recipients. These data lay the foundation for the European Union’s approval of Vancevi for the prevention of cytomegalovirus infection in organ transplant patients. The drug has been marketed both at home and abroad, and its picture is as follows:

The clinical studies that led to its approval evaluated the safety and effectiveness of Vancevir compared with Cytovene in preventing CMV infection in high-risk kidney, kidney-pancreas, liver and heart transplant patients whose donors were seropositive for CMV but whose recipients did not carry CMV antibodies. Roche said that Vancevir is a prodrug of Cytovene, which is currently widely used against cytomegalovirus. It can be quickly converted into the latter in the body, has greater bioavailability than the latter, and can be more conveniently administered once a day.

Roche is an internationally renowned company and a global pioneer and leader in the field of life sciences. It has always been committed to improving human life and health as its corporate mission. In the process of development, Roche Group not only leads the world in scientific research and development, and has developed and other therapeutic drugs, it is also committed to stimulating the innovation potential of both science and art by connecting art and technology.

Recommended hot articles: /newsDetail/90786.html